Should a pharmaceutical be approved for the broad indication of excessive sleepiness?
Pack
Allan I
AI
Division of Sleep Medicine, Department of Medicine, Center for Sleep and Respiratory Neurobiology, University of Pennsylvania, Philadelphia 19104, USA. pack@mail.med.upenn.edu
D001559:Benzhydryl Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D000697:Central Nervous System Stimulants / Q000494:pharmacology / Q000627:therapeutic use*; D006970:Disorders of Excessive Somnolence / Q000175:diagnosis / Q000188:drug therapy*; D017277:Drug Approval; D005260:Female; D006801:Humans; D008297:Male; D000077408:Modafinil; D017286:Polysomnography; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012891:Sleep Apnea Syndromes / Q000175:diagnosis / Q000188:drug therapy; D014481:United States; D014486:United States Food and Drug Administration
D001559:Benzhydryl Compounds; D000697:Central Nervous System Stimulants; D000077408:Modafinil